Adding Darzalex (daratumumab) to the treatment of multiple myeloma with Velcade (bortezomib) and dexamethasone significantly improved progression-free survival in a clinical trial of patients who…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
Empliciti (elotuzumab), a monoclonal antibody, is approved in both the U.S. and Europe as a treatment, in combination with Revlimid (lenalidomide) and Decatron (dexamethasone), for multiple myeloma patients who…
Juno Therapeutics and privately held biotech Eureka Therapeutics have entered into an immunotherapy development partnership with Memorial Sloan Kettering Cancer Center…
Elotuzumab in combination with bortezomib and dexamethasone prolongs the progression free survival of patients with relapsed or refractory multiple myeloma (RRMM), according to…
The Multiple Myeloma Research Foundation (MMRF) and the University of Michigan have partnered to provide multiple myeloma patients and their doctors access to…
In a video posted on Healio’s Hematology-Oncology page, Dr. Ola Landgren, chief of the myeloma service at Memorial Sloan Kettering Cancer Center…
